Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 15/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675597 | 0.83 | WNT3A (0.62) | WNT3AALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30398444 | 0.81 | WNT3A (0.47) | WNT3AALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22953919 | 0.75 | WNT3A (0.69) | WNT3A | |
| SCHEMBL1115477 | 0.75 | AKR1C3 (0.68) | ALDH1A1LMNAMAPT | |
| SCHEMBL30064367 | 0.74 | SCD (0.54) | — | |
| SCHEMBL30071306 | 0.74 | ABL1 (0.51) | DEGS1WNT3A | |
| SCHEMBL20262994 | 0.73 | L3MBTL1 (0.62) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29630875 | 0.72 | HRH3 (0.53) | — | |
| SCHEMBL3853696 | 0.72 | HRH3 (0.53) | — | |
| SCHEMBL22791547 | 0.72 | ALDH1A1 (0.61) | DEGS1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | DEGS1 2201/4885WNT3A 6/4885ALDH1A1 1128/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | DEGS1 2201/4885WNT3A 6/4885ALDH1A1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.